Thrombospondin‐1 Silencing Ameliorates Osteoblastic Differentiation of Aortic Valve Interstitial Cells via Inhibiting Nuclear Factor‐ κ B Pathway
Cardiovascular Therapeutics · 2025
DOI: 10.1155/cdr/3845211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Therapeutics, 2025. Verfasst von Qing Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Thrombospondin 1, Aortic Valve, NF-kappa B, Cell Differentiation. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: West China Hospital, Sichuan University, Department of Science and Technology of Sichuan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
Calcific aortic valve disease (CAVD) is a progressive cardiovascular condition driven by the osteogenic differentiation of valve interstitial cells (VICs), with no effective drug therapies currently available. Hence, our objective is to investigate the impact of thrombospondin‐1 (TSP‐1) silencing on CAVD progression.
Methods
In vitro experiments were employed using human primary VICs with TSP‐1 knockdown, cultured in osteogenic induction medium, and followed by analyses including western blot, alkaline phosphatase staining, alizarin red staining, immunofluorescence, and flow cytometry. In vivo experiments used two murine models of CAVD to determine the role of TSP‐1 silencing on aortic valve calcification.
Results
We observed that silencing of TSP‐1 reduced the osteogenic differentiation of VICs. Subsequent experiments demonstrated that TSP‐1 knockdown suppressed nuclear factor‐ κ B (NF‐ κ B)–mediated inflammation during osteoblastic differentiation of VICs. Consistent findings were also observed in two murine models of CAVD.
Conclusions
The present study has shown that TSP‐1 silencing could mitigate the development of CAVD by inhibiting NF‐ κ B‐mediated inflammation. We propose that targeting TSP‐1‐mediated NF‐ κ B pathway could provide a potential therapeutic method for treating CAVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, China.
- Cardiac Structure and Function Research Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.
- National Clinical Research Center for Geriatrics, The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
- Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Qing Li, Chengxiang Song, Zisong Wei, Junli Li, Hao Zhou, Shuoding Wang, Hongde Li, Haoran Yang, Qiang Luo, Mao Chen
Förderung
- West China Hospital, Sichuan University
- Department of Science and Technology of Sichuan Province
- National Natural Science Foundation of China
Zitieren
APA
Li, Q., Song, C., Wei, Z., Li, J., Zhou, H., Wang, S., Li, H., Yang, H., Luo, Q., & Chen, M. (2025). Thrombospondin‐1 Silencing Ameliorates Osteoblastic Differentiation of Aortic Valve Interstitial Cells via Inhibiting Nuclear Factor‐ κ B Pathway. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/3845211
Vancouver
Li Q, Song C, Wei Z, Li J, Zhou H, Wang S, et al. Thrombospondin‐1 Silencing Ameliorates Osteoblastic Differentiation of Aortic Valve Interstitial Cells via Inhibiting Nuclear Factor‐ κ B Pathway. Cardiovascular Therapeutics. 2025. doi:10.1155/cdr/3845211
BibTeX
@article{Li2025,
author = {Li, Qing and Song, Chengxiang and Wei, Zisong and Li, Junli and Zhou, Hao and Wang, Shuoding and Li, Hongde and Yang, Haoran and Luo, Qiang and Chen, Mao},
title = {Thrombospondin‐1 Silencing Ameliorates Osteoblastic Differentiation of Aortic Valve Interstitial Cells via Inhibiting Nuclear Factor‐ κ B Pathway},
journal = {Cardiovascular Therapeutics},
year = {2025},
doi = {10.1155/cdr/3845211}
}
EUVIMED